

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Health Technology Appraisal (MTA)

Deferasirox and deferiprone for the treatment of chronic iron overload in people with thalassaemia

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Apotex (deferiprone) • Hospira (deferasirox) • Novartis Pharmaceuticals UK (deferasirox) • Swedish Orphan Biovitrum (deferiprone) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Children • Action for Sick Children • Afiya Trust • Black Health Agency • Children's Society • Chinese National Healthy Living Centre • Counsel and Care • Equalities National Council • Genetic Alliance UK • Muslim Council of Britain • Muslim Health Network • National Children's Bureau • National Parent Partnership Network • Sickle Cell Society • South Asian Health Foundation • Specialised Healthcare Alliance • United Kingdom Thalassaemia Society • WellChild <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for Services to the Elderly • British Committee for Standards in 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • Public Health Wales NHS Trust • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Comparator manufacturer(s)</u> None</p> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • MRC Clinical Trials Unit • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • Liverpool Reviews & Implementation Group, University of Liverpool • National Institute for Health Research Health Technology Assessment

National Institute for Health and Clinical Excellence
Matrix for the technology appraisal of deferasirox and deferiprone for the treatment of chronic iron overload in people with thalassaemia

Consultees	Commentators (no right to submit or appeal)
<p>Haematology</p> <ul style="list-style-type: none"> • British Geriatric Society • British Society for Haematology • British Society for Human Genetics • NHS Sickle Cell & Thalassaemia Screening Programme • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum • UK Forum on Haemoglobin Disorders • United Kingdom Clinical Pharmacy Association • United Kingdom National Screening Committee <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Eastern and Coastal Kent Teaching • NHS Northamptonshire • Welsh Assembly Government 	<p>Programme</p> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Clinical Guidelines Centre <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • None

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Assessment Group (AG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.